Seres Therapeutics (Formerly Seres Health, Newco LS21)
Financials
Estimates*
| USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Revenues | 33.2m | 145m | 7.1m | 126m | 25.8m | 12.3m | 73.9m |
| % growth | (4 %) | 336 % | (95 %) | 1672 % | (80 %) | (53 %) | 504 % |
| EBITDA | (86.2m) | (62.7m) | (244m) | (94.3m) | (136m) | (120m) | (12.0m) |
| % EBITDA margin | (260 %) | (43 %) | (3425 %) | (75 %) | (528 %) | (980 %) | (16 %) |
| Profit | (89.1m) | (65.6m) | (250m) | (114m) | (102m) | (109m) | (66.6m) |
| % profit margin | (268 %) | (45 %) | (3509 %) | (90 %) | (395 %) | (890 %) | (90 %) |
| EV / revenue | 64.6x | 4.4x | 97.8x | 2.1x | 11.1x | 28.8x | 3.6x |
| EV / EBITDA | -24.9x | -10.1x | -2.9x | -2.8x | -2.1x | -2.9x | -22.6x |
| R&D budget | 90.6m | 142m | 173m | 146m | - | - | - |
| R&D % of revenue | 273 % | 98 % | 2426 % | 115 % | - | - | - |
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
$6.5m | Series A | ||
N/A | Series A | ||
| N/A | N/A | Series B | |
$48.0m | Series C | ||
$65.0m | Series D | ||
| N/A | N/A | IPO | |
* | N/A | $25.0m | Post IPO Equity |
* | $110m | Post IPO Debt | |
| Total Funding | $120m | ||
Related Content
Recent News about Seres Therapeutics (Formerly Seres Health, Newco LS21)
EditSeres Therapeutics is a pioneering company in the field of microbiome therapeutics, dedicated to transforming patient lives through innovative treatments. The company operates out of Cambridge, Massachusetts, where it houses its offices, research labs, and manufacturing facilities. Seres Therapeutics focuses on developing microbiome-based therapies, which involve using beneficial bacteria to treat various diseases. This approach is considered revolutionary because it targets the root cause of diseases by restoring the natural balance of bacteria in the human body.
The primary clients of Seres Therapeutics are patients suffering from conditions that can be treated through microbiome therapies, such as Clostridium difficile infection (CDI) and other gastrointestinal disorders. The company also collaborates with healthcare providers and research institutions to advance its therapeutic solutions.
Seres Therapeutics operates in the biopharmaceutical market, a sector known for its high growth potential and significant impact on public health. The company’s business model revolves around research and development (R&D), clinical trials, and the commercialization of its microbiome-based therapies. By investing heavily in R&D, Seres aims to bring cutting-edge treatments to market, thereby addressing unmet medical needs.
Revenue generation for Seres Therapeutics primarily comes from the sale of its approved therapies and potential licensing agreements with other pharmaceutical companies. Additionally, the company may receive funding through grants and partnerships aimed at advancing microbiome research.
In summary, Seres Therapeutics is a forward-thinking biopharmaceutical company focused on developing microbiome-based treatments to improve patient outcomes. It serves patients with specific medical conditions, operates in the biopharmaceutical market, and generates revenue through the sale and licensing of its innovative therapies.
Keywords: Microbiome, Therapeutics, Biopharmaceutical, Cambridge, R&D, Clinical Trials, Gastrointestinal, CDI, Healthcare, Innovation.